The Company received notice from SWOG regarding the analysis results of Phase II Stage 1 clinical trial of OBI-3424 in T-ALL and T-LBL

Date of occurrence of the event:2026/02/04 Company name:OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office Reciprocal shareholding ratios:NA Cause of occurrence: The Company has been collaborating with the Southwest Oncology Group (hereinafter referred to as “SWOG”) on a Phase I/II clinical trial in T-cell acute lymphoblastic leukemia (T-ALL) and […]